Amarin | AMRN - Des Atouts





Des Atouts Changement Date
AbbVie USD 147.68B 12.57B 2026-09
Alnylam Pharmaceuticals USD 7.99B 2.44B 2026-09
Amarin USD 634.08M 9.72M 2026-09
AstraZeneca USD 119.92B 4.09B 2026-09
BioCryst Pharmaceuticals USD 591.07M 33.22M 2026-09
DBV Technologies USD 215.4M 7.8M 2026-09
GlaxoSmithKline GBP 71.7B 9.96B 2026-09
Halozyme Therapeutics USD 3.47B 895.94M 2026-09
Heron Therapeutics USD 230.45M 21.81M 2026-09
Ionis Pharmaceuticals USD 2.91B 81.91M 2026-09
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Neurocrine Biosciences USD 5.63B 268.3M 2026-09
Novartis USD 117.15B 4.88B 2026-09